Antigen-specific immune tolerance in rheumatoid arthritis: opportunities and research priorities arising from the experience with Jusvinza
Keywords:
artritis reumatoide, tolerancia inmunológica, linfocitos T reguladores, JusvinzaAbstract
The clinical path of Jusvinza, an altered peptide ligand derived from the cellular stress protein HSP60, developed in Cuba and conditionally registered for rheumatoid arthritis since 2023, was summarized, and six issues of interest to the scientific community were raised: publication of controlled evidence, therapeutic positioning against valid comparators, response biomarkers, structural and glucocorticoid-sparing outcomes, long-term safety and immunogenicity, and extension to other indications. A national registry with common minimum variables is proposed to generate comparable evidence.
Downloads
References
Prada Hernández DM, Suárez Castellanos AA, Rodríguez Pérez K, Gómez Morejón JA, Morillo Rodríguez L, Nodarse Cuní H, et al. Efecto terapéutico de Jusvinza en pacientes con artritis reumatoide. Estudio del mundo real. Rev Cubana Reumatol. 2026;28:e1521.
Smolen JS, Landewé RBM, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3-18. doi:10.1136/ard-2022-223356
Fraenkel L, Bathon JM, England BR, St.Clair EW, Arayssi T, Carandang K, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2021;73(7):924-39. doi:10.1002/acr.24596
Gómez Morejón JA, Domínguez-Horta MC, Nodarse Cuní H, Prada Hernández DM. Pasado, presente y futuro de Jusvinza, para el tratamiento de la artritis reumatoide. Producto de la biotecnología cubana, desarrollado por el Centro de Ingeniería Genética y Biotecnología. Rev Cubana Reumatol. 2024;26:e1122.
Domínguez-Horta MC, Serrano-Díaz A, Hernández-Cedeño M, Martínez-Donato G, Guillén-Nieto G. A peptide derived from HSP60 reduces proinflammatory cytokines and soluble mediators: a therapeutic approach to inflammation. Front Immunol. 2023;14:1162739. doi:10.3389/fimmu.2023.1162739
Barberá A, Lorenzo N, van Kooten P, van Roon J, de Jager W, Prada D, et al. APL1, an altered peptide ligand derived from human heat-shock protein 60, increases the frequency of Tregs and its suppressive capacity against antigen responding effector CD4+ T cells from rheumatoid arthritis patients. Cell Stress Chaperones. 2016;21(4):735-44. doi:10.1007/s12192-016-0698-0
Prakken BJ, Samodal R, Le TD, Giannoni F, Yung GP, Scavulli J, et al. Epitope-specific immunotherapy induces immune deviation of proinflammatory T cells in rheumatoid arthritis. Proc Natl Acad Sci U S A. 2004;101(12):4228-33. doi:10.1073/pnas.0400061101
Koffeman EC, Genovese M, Amox D, Keogh E, Santana E, Matteson EL, et al. Epitope-specific immunotherapy of rheumatoid arthritis: clinical responsiveness occurs with immune deviation and relies on the expression of a cluster of molecules associated with T cell tolerance in a double-blind, placebo-controlled, pilot phase II trial. Arthritis Rheum. 2009;60(11):3207-16. doi:10.1002/art.24916
Prada D, Gómez J, Lorenzo N, Corrales O, López A, González E, et al. Phase I clinical trial with a novel altered peptide ligand derived from human heat-shock protein 60 for treatment of rheumatoid arthritis: safety, pharmacokinetics and preliminary therapeutic effects. J Clin Trials. 2018;8:339. doi:10.4172/2167-0870.1000339
Corrales O, Hernández L, Prada D, Gómez J, Reyes Y, López AM, et al. CIGB-814, an altered peptide ligand derived from human heat-shock protein 60, decreases anti-cyclic citrullinated peptides antibodies in patients with rheumatoid arthritis. Clin Rheumatol. 2019;38(3):955-60. doi:10.1007/s10067-018-4360-3
Prada Hernández DM, Gómez Morejón JA, Molinero Rodríguez C, Domínguez-Horta MC, Pozo Abreu SM, Reyes Pineda Y, et al. Comportamiento de la actividad clínica y la respuesta al tratamiento en pacientes con artritis reumatoide tratados con Jusvinza. Rev Cubana Reumatol. 2023;25(4):e1278.
Cantera Oceguera DT, Herrera Wong M, Leal Aguirre A, Domínguez Horta MC. Efecto terapéutico de Jusvinza en pacientes con artritis idiopática juvenil. Rev Cubana Pediatr. 2024;96:4668.
ClinicalTrials.gov. Safety, tolerability, and PK/PD of CIGB-814 in Chinese health participants [Internet]. Bethesda: U.S. National Library of Medicine; identificador NCT07182656 [citado 30 oct 2026]. Disponible en: https://clinicaltrials.gov/study/NCT07182656
Cantera Oceguera DT, Leal Aguirre A, Hernández Cedeño M, Domínguez Horta MC. Un nuevo esquema terapéutico con Jusvinza induce mejoría clínica y reduce moléculas asociadas con la inflamación en pacientes con artritis reumatoide y espondilitis anquilosante. Reporte de tres casos. Rev Cubana Reumatol. 2025;27:e1364.
Mustelier Mustelier LC, Sánchez Licea FA, Jiménez Jiménez de Castro Y. Uso de Jusvinza como terapia inmunomoduladora en el Chikungunya. Rev Cubana Reumatol. 2026;28:e1490.
Registro Público Cubano de Ensayos Clínicos. Jusvinza in adult patients with rheumatoid arthritis from Camaguey and Eastern Provinces (MARIANA) [Internet]. La Habana: Centro Nacional Coordinador de Ensayos Clínicos; identificador RPCEC00000433 [citado 30 oct 2026]. Disponible en: https://rpcec.sld.cu/ensayos/RPCEC00000433-Sp
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Dr. Eduardo Antonio Hernández González
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Warning of rights of author
The authors that publish in this journal agree with the following terms:
The authors conserve the rights of author and concede to the journal the right of the first publication, fulfilling with the license Creative Commons Attribution License that allows to others share the work with recognition of the authorship of their articles, and the initial publication in this journal.
The authors can establish separately additional agreements for the no exclusive distribution of the version of the work published in the journal (for example, situate it in an institutional repository, in a personal blog or publish it partial or totally in a book), with a recognition of their initial publication in this journal.
To be able to send the manuscript or part of him passed three months of published, for his evaluation to other publishers, identifying it or not with the same title; whenever allusion is made to our journale and know it the new publisher.
The publishing committee of the Cuban Journal of Rheumatology authorizes to other publishers, to reproduce the articles published in our magazine, whenever it indicate the origin of the same.
The authors should send a document in Office Word application format through the electronic address of the magazine with a similar format to that we include next:
---------------------------------------------------------------------------------------------------------------------
Statement of authorship and cede of articles for the publication of the scientific work in the Cuban Journal of Rheumatology
Date:
Those who subscribe certify that are the authors of the work:
Of this form communicate the originality of our article clearing that the concepts and knowledges of other authors that have included in the text of the article, have been quoted properly in the bibliography.
We do proof besides that the article in question is original and has not been published, total neither partially, in another journal.
To be approved for his publication in the Cuban Journal of Rheumatology, do secession of the rights of publication to the same one through the method that realizes it usually.
In front of any catchword that exist by the article that send to evaluate, relieve of of the responsibility to the Cuban Journal of Rheumatology holding us responsible with all the difficulties that can berelated by any situation.
We include to continuation the name and the signature of all authors and collaborators of this article.
Name: Signature:
